Key facts
- Expedition Therapeutics’s last known valuation is $221.0M (Oct 2025).
- It has raised $165.0M; the latest was Early Stage VC ($165.0M) in Oct 2025.
- Notable investors include Novo Holdings, Venrock, Forbion, Logos Capital, Adage Capital Management — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Expedition Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Expedition Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Expedition Therapeutics
Operator of biopharmaceutical development services intended for translational research and global licensing purposes. The company's platform identifies and in-licenses novel therapeutic candidates, conducts preclinical and clinical validation, manages regulatory pathways and commercialization partnerships, enabling pharmaceutical firms and investors to access promising assets from emerging markets, accelerate development timelines, and expand international pipelines efficiently.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 3
- Website
- expeditiontx.com/
- Ownership
- Privately Held (backing)
Expedition Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Expedition Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Expedition Therapeutics in its N-PORT filings yet. We sweep new filings monthly.